Onconetix, Inc. (NASDAQ:ONCO - Get Free Report) saw a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 1,840,000 shares, a decrease of 70.8% from the May 15th total of 6,300,000 shares. Based on an average daily trading volume, of 22,310,000 shares, the short-interest ratio is presently 0.1 days. Currently, 6.4% of the company's stock are sold short.
Onconetix Stock Performance
Shares of Onconetix stock traded down $0.47 during midday trading on Monday, hitting $4.26. The company had a trading volume of 228,841 shares, compared to its average volume of 103,913. The company has a 50 day moving average of $6.08 and a 200 day moving average of $24.57. Onconetix has a 52-week low of $4.05 and a 52-week high of $1,190.00.
Onconetix (NASDAQ:ONCO - Get Free Report) last issued its earnings results on Thursday, June 12th. The company reported $21.25 EPS for the quarter. The business had revenue of $0.10 million for the quarter.
Wall Street Analyst Weigh In
Separately, Wall Street Zen upgraded Onconetix to a "hold" rating in a research note on Saturday.
Read Our Latest Research Report on ONCO
Institutional Trading of Onconetix
A hedge fund recently bought a new stake in Onconetix stock. Millennium Management LLC bought a new stake in shares of Onconetix, Inc. (NASDAQ:ONCO - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 39,477 shares of the company's stock, valued at approximately $25,000. Millennium Management LLC owned about 0.48% of Onconetix at the end of the most recent quarter. Institutional investors own 23.89% of the company's stock.
About Onconetix
(
Get Free Report)
Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Featured Articles
Before you consider Onconetix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Onconetix wasn't on the list.
While Onconetix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
